7. Clinical benefit table: Artz versus Hylan G‐F 20. Continuous outcome measure.

Study	Time	Treatment	Outcome	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Karlsson 2002c	1‐4 wk	E: Artzal	Pain on weight bearing (0‐100 mm VAS)	92	64	44	‐2 (I)	‐3.2% (I)
		C: Hylan G‐F 20		88	63	45
Karlsson 2002c	5‐13 wk	E: Artzal	Pain on weight bearing (0‐100 mm VAS)	92	64	42	0	0%
		C: Hylan G‐F 20		88	63	41
Karlsson 2002c	14‐26 wk	E: Artzal	Pain on weight bearing (0‐100 mm VAS)	92	64	48	4 (W)	6.3% (W)
		C: Hylan G‐F 20		88	63	43
Karlsson 2002c	5‐13 wk	E: Artzal	WOMAC (0‐100 mm VAS)	92	48.7	34.7	3.0 (W)	6.2% (W)
		C: Hylan G‐F 20		88	48.7	31.7
Karlsson 2002c	14‐26 wk	E: Artzal	WOMAC (0‐100 mm VAS)	92	48.7	37.4	5.5 (W)	11.3% (W)
		C: Hylan G‐F 20		88	48.7	31.9
Karlsson 2002c	14‐26 wk	E: Artzal	Lequesne Index (0‐24)	92	13.9	10.0	0.5 (W)	3.7% (W)
		C: Hylan G‐F 20		88	13.4	9.0